The purpose of these grants is to support the development of outstanding Canadian research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. Investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research.
Bladder Cancer Canada Research Grant Recipients
2024 Recipients
Dr. Peter Black:
Tumor microenvironment transcriptional heterogeneity in neoadjuvant therapy response prediction in MIBC
Dr. Vincent Fradet:
Boosting the response to BCG immunotherapy: Harnessing the gut microbiota for bladder cancer treatment
Dr. Charles Graham:
Systemic immune reprogramming and response to BCG therapy in patients with bladder cancer
Dr. Amina Zoubeidi:
Epigenetic regulation of neuroendocrine differentiation in urothelial bladder cancers
2023 Recipients
Dr. Stephane Bolduc:
Investigate how Bisphenol (a chemical used in manufacturing plastics) induces changes in the cancerous connective tissue of lab-grown bladders.
Dr. Indra Gupta:
Study Osr1, a tumour suppressor gene that can lose its suppressing ability, and its important role in the development of bladder cancer.
Dr. Madhuri Koti:
Monitoring the immune system response to treatment in patients with non-muscle invasive bladder cancer who did not respond to BCG immunotherapy because of a biological sex-based reduction in immune system functioning.
Dr. Charles Graham:
Improvements in immune system function/response from BCG immunotherapy in patients with bladder cancer.
Dr. Wassim Kassouf:
How immune system anti-tumour cell functionality in patients with muscle invasive bladder cancer affects the outcome of radiation therapy.
Dr. Dirk Lange:
How microorganisms (e.g., bacteria) that live in the bladder affect the outcome of BCG-induced immunotherapy for patients with bladder cancer.
2022 Recipients
Dr. Luke Lavallee:
Decision aid for patients with muscle invasive bladder cancer
Dr. Jayachandtan Kizhakkedathu:
Development of an Infigratinib-eluting Device for Localized Treatment of NMIBC
Dr. Peter Black:
Circulating immune cells of patients with BCG-unresponsive NMIBC treated with atezolizumab
Dr. Paul Toren:
Circulating basophlis and the tumor immune microenvironment of NMIBC
Dr. Girish Kulkarni:
Early warning system for NMIBC recurrence and progression
To review previous recipients, please click here.
Research Papers Supported
- Obesity and Complication Risk From Radical Cystectomy: Identifying a Body Mass Index Threshold
- Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
- Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic